WALL STREET JOURNAL | Recent bankruptcy of drug developer Achaogen reflects industry struggling to meet challenge of drug-resistant bacteria
WALL STREET JOURNAL | Recent bankruptcy of drug developer Achaogen reflects industry struggling to meet challenge of drug-resistant bacteria